Экономический анализ применения вакцины против вируса папилломы

01.11.2010

Литература

  1. Alexandrova Y.N., Lyshchov A.A., Safronnikova N.R. et al. Features of HPV infection among the healthy attendants of gynecological practice in St. Petersburg, Russia // Cancer Lett. 1999, Oct. 18; 145 (1 - 2): 43 - 48.
  2. Bergeron C., Cartier I., Guldner L. et al. Lesions precancereuses et cancers du col de l'uterus diagnostiques par lefrottis cervical, Ile-de-France, enquete Crisap, 2002 // Bulletin Epidemiologique Hebdomadaire. 2005; (2): 5 - 8.
  3. Castellsague X., de Senjos S., Aguado т. et al. HPV and cervical cancer in the World: 2007 report // Vaccine. 2007; 25 (Suppl. 3): C1 - C230.
  4. Castellsague X. Natural history and epidemiology of HPV infection and cervical cancer // Gynecol. Oncol. 2008 Sep.; 110 (3 Suppl. 2): S4 - S7. Review.
  5. Clifford G., Franceschi S., Diaz M. et al. Chapter 3: HPV type-distribution with and without cervical neoplastic deseases // Vaccine. 2006; 24 (Suppl. 3): 26 - 34.
  6. Clifford G.M., Rana R.K., Franceschi S. et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer // Cancer Epidemiol. Biomarkers Prev. 2005; 14 (5): 1157 - 1164.
  7. Paavonen J., Naud P., Salmeron J. еt al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIYA): final analysis of a double-blind, randomized study in young women // Lancet. 2009; 374: 301 - 314.
  8. Skinner R. Apter D.L., Chow S.N. et al. Cross-protection efficacy of Cervarix™ against oncogenic HPV types beyond HPV-16/18. (Abstract n° O-29.01 presented at the 25 IPV Conference, May, Malmo, Sweden), 2009.
  9. Smith J.S., Lindsay L., Hoots B. et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update // Int. J. Cancer. 2007; 121 (3): 621 - 632.
  10. Tjalma W., Arbyn M., Paavonen J. et al. Efficacy of the HPV-16/18 AS04-adjuvanted vaccine against abnormal cytology and low-grade histo-pathological lesions in an oncogenic HPV-naive population. (Abstract № A-171-0004-01446 presented at the 16th International Meeting of the European Society for Gynaecological Oncology (ESGO), 11 - 14 Oct., Belgrade, Serbia, 2009.)
  11. Вестник РОНЦ им. Н.Н. Блохина РАМН. 2009. Т. 20. № 3. Прил. 1.
  12. Профилактика рака шейки матки: Руководство для врачей. Утв. заместителем министра здравоохранения и социального развития РФ В.И. Стародубовым. - М.: МЕДпресс-информ, 2008.